Full Text View
Tabular View
No Study Results Posted
Related Studies
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors (NET)
This study is currently recruiting participants.
Verified July 2012 by Assistance Publique - Hôpitaux de Paris
Study NCT01215578   Information provided by Assistance Publique - Hôpitaux de Paris

First Received on September 23, 2010.   Last Updated on July 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neuroendocrine Tumors
Pancreatic Neoplasms
Advanced Disease
Sunitinib
Additional conditions recognized in this trial
Endocrine Gland Neoplasms
Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Endocrine System Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Pancreatic Diseases
Interventions listed in this trial
Sutent
Additional drug interventions recognized in this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Physiological Effects of Drugs
Sunitinib
More general drug interventions related to this trial
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Assistance Publique - Hôpitaux de Paris


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services